

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Bee Vectoring Technologies International Inc. (the "Issuer").

Trading Symbol: BEE

Number of Outstanding Listed Securities: 191,436,373 common shares ("Shares") were issued and outstanding as of April 30, 2024

Date: May 6, 2024 (for the month of April 2024)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer, an agriculture technology company, is a market disruptor with a significant global market opportunity in the \$240 billion crop protection and fertilizer market. The Issuer has pioneered a natural precision agriculture system that replaces chemical pesticides and wasteful plant protection product spray applications by delivering biological pesticide alternatives to crops using commercially grown bees. The Issuer's award-winning technology, precision vectoring, is completely harmless to bees and allows minute amounts of naturally-derived pesticides (called biologicals) to be delivered directly to blooms, providing improved crop protection and yield results than traditional chemical pesticides - and improving the health of the soil, the microbiome and the environment. Currently, the Issuer has over 65 granted patents, over 35 patents pending in all major agricultural countries worldwide, and has US EPA registration of its VECTORITE™ with CR-7 (EPA Registration No. 90641-2) for sale as a registered biological fungicide for use on the labelled crops.

2. Provide a general overview and discussion of the activities of management.

During the month of April 2024, management's principal activities consisted of:

- closing a debt settlement to a bona fide creditor of the Issuer through the issuance of 937,540 common shares in the capital of the Issuer issued at a deemed price of \$0.039887023 per share, based on a 20-day VWAP, in full satisfaction of outstanding cash payments due in the amount of \$37,395.68;
- announcing strong spray trial results for its proprietary *Clonostachy rosea* CR-7 ("CR-7") biofungicide;
- closing a debt settlement to a consultant of the Issuer through the issuance of 11,037,485 common shares in the capital of the Issuer at a deemed price of \$0.035 per share, in full satisfaction of outstanding cash payments due in the amount of 386,312; and
- attending to general administrative matters.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

During the month of April 2024, the Issuer announced strong spray trial results for its proprietary CR-7 biofungicide.

Data from the Michigan State University trial shows that when used on a blueberry crop, the Issuer's CR-7 reduced early disease infection (shoot strikes) and Monilinia (mummy berry) fungal disease by over 90% compared to the untreated plot, and was equally effective as the grower standard (the conventional use of chemical treatments) when used as a spray application.

Mummy berry, caused by the fungus Monilinia vaccinii-corymbosi, is a major blueberry pathogen that causes yield and quality loss. Primary infections, called shoot strikes, can result in bush dieback and can be a source for secondary infections later in the season. Fruit "mummification" is not evident in early stages of development, but as the fruit develops, infected berries turn pink or light brown and eventually shrivel up. These shriveled berries then provide inoculum for subsequent seasons, resulting in a perennial pest pressure if not managed proactively.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of April 2024.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

There were no new business relationships entered into by the Issuer during the month of April 2024.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

No contracts or agreements between the Issuer, the Issuer's affiliates or third parties expired or were cancelled and no previously announced financing arrangements were cancelled during the month of April 2024.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions or dispositions of the Issuer's assets during the preceding month of March 2024.

8. Describe the acquisition of new customers or loss of customers.

There were no new customers or loss of customers during the month of April 2024.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products that occurred during the month of April 2024.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of April 2024.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of April 2024.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became party to during the month of April 2024.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

During the month of April 2024, the Issuer repaid \$100,000 in Notes by converting the Notes into 2,600,000 Common Shares at a price of \$0.05 per common share (the “**Conversion**”). This Conversion included a 10% repayment penalty fee and a 20% facilitation fee payable to the noteholders.

14. Provide details of any securities issued and options or warrants granted.

During the month of April 2024, the following securities were issued:

Security	Number Issued	Details of Issuance	Use of Proceeds
Common shares	937,540	Common shares issued pursuant to a debt settlement at a deemed price of \$0.039887023 per common share,	\$37,395.68 in debt was extinguished

		based on a 20-day VWAP.	
Common shares	1,275,000	Conversion of RSUs	Not applicable
Common shares	2,508,155	Conversion of RSUs	Not applicable
Common shares	11,037,485	Common shares issued pursuant to a debt settlement at a deemed price of \$0.035 per common share.	\$386,312 in debt was extinguished
Secured promissory notes	\$100,000	\$100,000 in secured promissory notes issued pursuant to Loan Agreement dated December 11, 2023	Working Capital
Common shares	2,600,000	Conversion of the 3rd tranche of \$100,000 in secured promissory notes, including a 10% repayment penalty fee and a 20% facilitation fee payable to the noteholders	\$100,000 in Notes was extinguished
RSUs	3,539,625	RSUs issued to employees and consultants pursuant to the Issuer's restricted share unit plan in lieu of certain cash payments for future services	Not applicable

15. Provide details of any loans to or by Related Persons.

There were no loans made to or by Related Persons of the Issuer during the month of April 2024.

16. Provide details of any changes in directors, officers or committee members.

As at April 30, 2024, the directors and officers of the Issuer are as follows:

Ashish Malik	Director, Chief Executive Officer, President and member of the audit committee
Kyle Appleby	Chief Financial Officer and Corporate Secretary
Michael Collinson	Director, Chairman and member of the audit committee

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's MD&A for the period ended December 31, 2023 dated as of February 29, 2024 under the headings "FINANCIAL INSTRUMENTS", "OTHER RISKS AND UNCERTAINTIES" and "RISKS AND UNCERTAINTIES". The MD&A is available on the Issuer's SEDAR+ profile at www.sedarplus.ca.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 6, 2024

Ashish Malik
Name of Director or Senior
Officer

"Ashish Malik"
Signature

President & CEO
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer		YYYY/MM/D
Bee Vectoring Technologies International Inc.	April 2024	2024/05/06
Issuer Address		
4160 Sladeview Crescent, #7		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Mississauga, ON L5L 0A1	(604) 687-3141	(604) 687-2038
Contact Name	Contact Position	Contact Telephone No.
Ashish Malik	President & CEO	(604) 687-2038
Contact Email Address	Web Site Address	
amalik@beevt.com	http://www.beevt.com/	